A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418

NCT05995782 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease Psychosis
Amyotrophic Lateral Sclerosis (ALS)

Interventions

DRUG: FB418

Sponsor

1ST Biotherapeutics, Inc.